Glaxosmithkline (GSK)

 

GSK Share PerformanceMore

52 week high1,745.5 11/10/16
52 week low1,446.5 06/12/16
52 week change 229.0 (15.45%)
4 week volume165,360,195 31/05/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Insurers and utilities drag FTSE lower

Investor sentiment remained subdued as insurance and utility stocks weighed on the FTSE. Direct Line (DLG) fell 1.9% to 3...

Director/PDMR Shareholding

RNS Number: 7867I GlaxoSmithKline PLC 21 June 2017 GlaxoSmithKline plc (the ' Company ') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mrs V A Whyte b) Position/status Company Secretary c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, auct...

GSK to unveil Zoster-048 clinical study results

GSK has confirmed that it will be presenting new results from a clinical study showing that its candidate vaccine for the p...

GSK presents Shingrix PhIII study results at ACIP

RNS Number: 7784I GlaxoSmithKline PLC 21 June 2017 Issued: 21 June 2017, London UK - LSE GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC's Advisory Meeting Study conducted in individuals who had previously received current standard of care GSK [LSE/NYSE: GSK] today will be presenting new...

GSK confirms start date for Luke Miels

GlaxoSmithKline has confirmed that Luke Miels would start his appointment as president, global pharmaceuticals, on 4 Se...

GSK confirms start date for Luke Miels

RNS Number: 5167I GlaxoSmithKline PLC 19 June 2017 Issued: Monday 19 June 2017, London UK - LSE GSK confirms start date for Luke Miels GSK has reached an agreement with AstraZeneca that Luke Miels will commence his appointment as President, Global Pharmaceuticals, GSK on 4 September 2017 . GSK enquiries: UK Media enquiries: Simon Steel +44 (0) 20...

The week ahead: Big day for Sirius Minerals

The FTSE reshuffle takes effect Monday, while investors get an update from a retailer just days after grim retail sales data...

Broker Forecast - Jefferies International issues a broker note on GlaxoSmithKline PLC

Jefferies International today reaffirms its buy investment rating on GlaxoSmithKline PLC (LON:GSK) and raised its price...

Fundamental DataMore

P/E ratio91.011
EPS18.8
Dividend yield4.676 %

Latest discussion posts More

  • Re: Day 20

    Games I have never been a Woody watcher, childish really to gloat at seeing the so called kings falling, but entertaining (and I appreciate the calculations) to watch the ...
    26-Jun-2017
    foolish learner
  • Day 20

    Summary Day 19 - GSK retaining an above 11% lead at 11.09% Today GSK edges up 0.15% in a strong up market and Lloyds gets another battering down 0.27% -- swing to GSK is ...
    26-Jun-2017
    gamesinvestor
  • Re: Oncology - IO Drug Space

    And a tired old bunch of drugs they were too. Witty got a very good price for them if my memory serves me correctly. Would not expect Woody to hand out plaudits as his ...
    26-Jun-2017
    sound money

Users' HoldingsMore

Users who hold Glaxosmithkline also hold..
VODAFONE GRP.35%
BP35%
NATIONAL GRID32%
LLOYDS GRP.32%
RDS 'B'31%

Codes & Symbols

ISINGB0009252882
SymbolsGSK, LSE:GSK, GSK.L, GSK:LN, LON:GSK, XLON:GSK